Detalhe da pesquisa
1.
Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.
Haemophilia
; 29(4): 1142-1149, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335569
2.
The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.
J Thromb Thrombolysis
; 55(3): 449-463, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746885
3.
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
Br J Clin Pharmacol
; 88(7): 3447-3462, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35014061
4.
Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.
Pulm Pharmacol Ther
; 56: 86-93, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917927
5.
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
Clin Transl Sci
; 17(4): e13784, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563414
6.
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.
Thromb J
; 11(1): 10, 2013 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23809871
7.
Predictive value for increased activated factor XI activity in acute venous thromboembolism.
J Thromb Haemost
; 21(6): 1610-1622, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003466
8.
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
J Thromb Haemost
; 20(7): 1684-1695, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35490404
9.
Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis.
Sci Rep
; 12(1): 9761, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697739
10.
Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism.
Thromb Res
; 220: 75-87, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36274391
11.
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
J Thromb Haemost
; 19(10): 2407-2416, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192419
12.
Clinical use of thrombin generation assays.
J Thromb Haemost
; 19(12): 2918-2929, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592058
13.
Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine.
J Thromb Haemost
; 19(12): 2907-2917, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525255
14.
A high-sensitivity, medium-density, and target amplification-free planar waveguide microarray system for gene expression analysis of formalin-fixed and paraffin-embedded tissue.
Clin Chem
; 55(11): 1995-2003, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19745061
15.
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.
Res Pract Thromb Haemost
; 3(2): 242-253, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31011708
16.
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.
Clin Pharmacol Drug Dev
; 2(3): 270-7, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121789
17.
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study.
Pharmaceuticals (Basel)
; 5(3): 279-96, 2012 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24281379
18.
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Thromb Haemost
; 108(1): 191-8, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22534775
19.
Stochastic pairing of Ig heavy and light chains frequently generates B cell antigen receptors that are subject to editing in vivo.
Int Immunol
; 17(4): 343-50, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15710909